{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:08:45Z","timestamp":1761718125751},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.2215\/cjn.05570809","type":"journal-article","created":{"date-parts":[[2010,1,8]],"date-time":"2010-01-08T03:51:13Z","timestamp":1262922673000},"page":"379-385","source":"Crossref","is-referenced-by-count":29,"title":["Dialysis and Transplantation in Fabry Disease"],"prefix":"10.2215","volume":"5","author":[{"given":"Renzo","family":"Mignani","sequence":"first","affiliation":[]},{"given":"Sandro","family":"Feriozzi","sequence":"additional","affiliation":[]},{"given":"Roland M.","family":"Schaefer","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Breunig","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Paulo","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[]},{"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-35-20230601","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"R2-35-20230601","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore"},{"key":"R3-35-20230601","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"R4-35-20230601","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"R5-35-20230601","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"R6-35-20230601","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"R7-35-20230601","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet Med"},{"key":"R8-35-20230601","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: Changing pattern of causes of death in FOS-Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J Med Genet"},{"key":"R9-35-20230601","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: A randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"R10-35-20230601","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"R11-35-20230601","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States","volume":"61","author":"Thadhani","year":"2002","journal-title":"Kidney Int"},{"key":"R12-35-20230601","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/TP.0b013e318191a842","article-title":"Kidney transplant outcomes in patients with Fabry disease","volume":"87","author":"Shah","year":"2009","journal-title":"Transplantation"},{"key":"R13-35-20230601","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R14-35-20230601","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R15-35-20230601","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R16-35-20230601","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R17-35-20230601","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000168482","article-title":"Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry Disease","volume":"29","author":"Feriozzi","year":"2009","journal-title":"Am J Nephrol"},{"key":"R18-35-20230601","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R20-35-20230601","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R21-35-20230601","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: A randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"R22-35-20230601","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ndt\/11.supp7.4","article-title":"Report on management of renale failure in Europe, XXVI,: Rare diseases in renal replacement therapy in the ERA-EDTA Registry","volume":"11","author":"Tsakiris","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"R23-35-20230601","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","article-title":"Results of a nationwide screening for Anderson-Fabry disease among dialysis patients","volume":"15","author":"Kotanko","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R24-35-20230601","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfl528","article-title":"A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population","volume":"22","author":"Merta","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R25-35-20230601","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"R26-35-20230601","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","article-title":"Excellent outcome of renal transplantation in patients with Fabry\u2019s disease","volume":"69","author":"Ojo","year":"2000","journal-title":"Transplantation"},{"key":"R27-35-20230601","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/ndt\/gfm096","article-title":"Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.","volume":"22","author":"Pastores","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R28-35-20230601","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1523-1755.2004.00883.x","article-title":"Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease","volume":"66","author":"Kosch","year":"2004","journal-title":"Kidney Int"},{"key":"R29-35-20230601","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2005.03.016","article-title":"Enzyme replacement therapy in Fabry disease patients undergoing dialysis: Effects on quality of life and organ involvement","volume":"46","author":"Pisani","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R30-35-20230601","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/ndt\/gfm813","article-title":"Agalsidase therapy in patients with Fabry disease on renal replacement therapy: A nationwide study in Italy","volume":"23","author":"Mignani","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R31-35-20230601","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/j.ajkd.2009.01.261","article-title":"Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: The choices for healthy outcomes in caring for ESRD (CHOICE) study","volume":"54","author":"Sozio","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R32-35-20230601","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"R33-35-20230601","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Widemann","year":"2009","journal-title":"Circulation"},{"key":"R34-35-20230601","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","article-title":"Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study","volume":"65","author":"Mignani","year":"2004","journal-title":"Kidney Int"},{"key":"R35-35-20230601","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1432-2277.2008.00824.x","article-title":"Kidney transplantation in patients with Fabry disease","volume":"22","author":"Cybulla","year":"2009","journal-title":"Transpl Int"},{"key":"R36-35-20230601","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/ndt\/gfp105","article-title":"Nephropathy in Fabry disease: The importance of early diagnosis and testing in high-risk populations","volume":"24","author":"\u00d6qvist","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R37-35-20230601","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s101570050061","article-title":"Fabry disease in patients receiving maintenance dialysis","volume":"4","author":"Utsumi","year":"2000","journal-title":"Clin Exp Nephrol"},{"key":"R39-35-20230601","first-page":"113","article-title":"Screening for Fabry disease in endstage nephropathies","volume":"25","author":"Spada","year":"2002","journal-title":"J Inher Metabol Dis"},{"key":"R41-35-20230601","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/ndt\/gfg194","article-title":"alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease","volume":"18","author":"Linthorst","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R43-35-20230601","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s10157-005-0369-4","article-title":"Significance of screening for Fabry disease among male dialysis patients","volume":"9","author":"Ichinose","year":"2005","journal-title":"Clin Exp Nephrol"},{"key":"R44-35-20230601","doi-asserted-by":"crossref","first-page":"c33","DOI":"10.1159\/000085709","article-title":"Fabry disease in patients with end-stage renal failure: the potential benefits of screening","volume":"101","author":"Bekri","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"R45-35-20230601","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5414\/CNP64281","article-title":"Identification of Fabry\u2019s disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients","volume":"64","author":"Tanaka","year":"2005","journal-title":"Clin Nephrol"},{"key":"R47-35-20230601","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/ndt\/gfm532","article-title":"Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population","volume":"23","author":"Terryn","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R48-35-20230601","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2215\/CJN.02490607","article-title":"Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test","volume":"3","author":"Andrade","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R49-35-20230601","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/08860220802353777","article-title":"Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report","volume":"30","author":"Porsch","year":"2008","journal-title":"Ren Fail"},{"key":"R51-35-20230601","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1432-2277.2008.00791.x","article-title":"Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria","volume":"22","author":"Kleinert","year":"2009","journal-title":"Transpl Int"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01277230-201002000-00035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T22:06:15Z","timestamp":1685657175000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01277230-201002000-00035"}},"subtitle":["Indications for Enzyme Replacement Therapy"],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.05570809","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}